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Background: Cervical cancer is the most common malignancy
in Indian women and approximately 130,000 women fall prey to
cervical cancer every year. HPV DNA testing can be used as an
adjunct to cytological screening of cervical samples of above 30
year old women and can be used as an optional test for follow-up
in women who have slightly abnormal Pap test results. The aim of
the study was to assess the HPV 16 and 18 status in cervical cancer
patients and in healthy women visiting JIPMER, Pondicherry.
Methods&Materials: This studywas approvedby JIPMER Insti-
tute Ethics Committee. 171 biopsies from cervical cancer patients
and 152 cytobrush samples from healthy women were collected.
DNA was extracted using QIAamp DNA mini kit. The quality and
quantity of the extracted DNA was determined by a spectropho-
tometer. The integrity of genomic DNA was checked by amplifying
a 248-bp product of the human beta-globin housekeeping gene. A
nested multiplex PCR was standardized and carried out to detect 2
high risk types, HPV 16 and HPV 18, further representative positive
PCR amplicons were sequenced for conﬁrmation.
Results: Out of 171 cervical cancer cases, 149 (87%) patient sam-
ples tested positive. Overall HPV-16 and18 occurrence was found
to be 87% in which HPV-16 was 64%, HPV 18 was 3% and mixed
infection was 23%. Out of 152 healthy women cases, 78 samples
were positive. Overall HPV-16 and18 occurrence was found to be
51% in which HPV-16 was 22%, HPV 18 was 5% and mixed infec-
tion was 25%. Sequencing results were analyzed in NCBI BLAST to
reconﬁrm the HPV genotype.
Conclusion: In our study,HPV -16 found tobe themost common
genotype in our region. Our study suggests that the HPV 16 and 18
mixed infection could be due to the consequence of poor genital
hygiene and unsafe sexual behavior. In healthy women cases, it
may be too early to come to a deﬁnitive conclusion about the HPV
positivity because women under 30 who are sexually active are
likely to have an HPV infection that will disappear on its own in
future. But those women may need regular follow up.
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Is HLA-DRB1*13 allele a risk factor for prognosis
of hepatitis C virus infection?
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Background: Hepatitis C virus infection, with its high rate of
chronicity, is a serious public health problem. There are studies
being conducted on the factors affecting the prognosis of the dis-
ease. Changes of alleles in the human histocompatibility antigens
(HLA)havebeen reported toaffect theprognosisofHCV infection. In
this study, we aimed to investigate the effects of HLA-DRB1 alleles
on the treatment response and prognosis of the HCV infection.
Methods & Materials: This study was conducted with a total
of 65 chronic HCV patients at Adnan Menderes University Medi-
cal Faculty Hospital. These patients were divided into three groups
according to the prognosis of the disease: 1) patients who have
responded to the treatment, 2) patients who has not responded to
the treatmentorhad recurrenceof thedisease, 3)patientswhohave
recovered spontaneously. Determination of HLA-DRB1 alleleswere
performed using sequence speciﬁc oligonucleotide (SSO)-Luminex
method.
Results: The patients were in 22-79 years age range, and the
averge age was 56.5 ± 12.9. 43.1% of the patients (28) were male,
and 56.9% (37) were female. Of the 65 patients with HCV infection
in the study, 36 (% 55.4) responded to the treatment, 16 (24.6%) has
not responded to the treatment or had recurrence of the disease, 13
(20%) have recovered spontaneously. Themost commonHLA-DRB1
alleles types found in patients were: HLA-DRB1*11 in 34 patients
(26.15%), HLA-DRB1*4 in 20 patients (15.38%), HLA-DRB1*15 in 14
patients (10.17%), HLA-DRB1*13 in 13 patients (10%), HLA-DRB1*1
in 11 patients (8.46%). The patients who responded to treatment
and patientswho recovered spontaneouslywere found to carry the
most HLADRB1*11 allele. The patients who have not responded to
treatmentorhad recurrenceof thediseasewere found tocarryHLA-
DRB1*13 allele the most, A statistically signiﬁcant relationship (p
<0.002) was found between frequency of HLA-DRB1*13 allele and
the response to treatment and prognosis of the disease.
Conclusion: We concluded that carrying the HLA-DRB1*13
allelemaybea risk factor forprognosis and response to treatmentof
HCV infection. Therefore, determination of HLA-DRB1 alleles may
be necessary for effective treatment planning for patientswithHCV
infection.
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